Dulcolax vs Placebo in Functional Constipation

Constipation Clinical Trial

Official title:

A Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of 4 Weeks Treatment With Bisacodyl (Dulcolax) Tablets 10mg Administered Orally, Once Daily, in Patients With Functional Constipation.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00526097
• Other study ID #: 122.56
• Secondary ID: EUDRACT 2007-001
• Status: Completed
• Phase: Phase 3
• First received: September 5, 2007
• Last updated: December 13, 2013
• Start date: September 2007

Study information

• Verified date: December 2013
• Source: Boehringer Ingelheim
• Contact: n/a
• Is FDA regulated: No
• Health authority: Great Britain: MHRA
• Study type: Interventional

Clinical Trial Summary

The objective of the study was to compare the efficacy and safety of 4 weeks treatment with bisacodyl (Dulcolax) tablets 10 mg to placebo in patients with functional constipation. In addition, the effect of treatment on quality of life and general health status was evaluated.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 368
• Est. primary completion date: June 2009
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Male and female patients, aged 18 and above

2. Suffering from functional constipation, according to their medical history, as defined by the Rome III diagnostic criteria , i.e.:Criteria fulfilled for the last 3 months with symptom onset at least 6 months prior to diagnosis.

1. Must include 2 or more of the following::

• straining during at least 25% of the defecations

• lumpy or hard stools in at least 25% of the defecations

• sensation of incomplete evacuation for at least 25% of the defecations

• sensation of anorectal obstruction/blockade for at least 25% of the defecations

• manual manoeuvres to facilitate at least 25% of the defecations (e.g. digital evacuation, support of the pelvic floor)

• fewer than 3 defecations per week

2. Loose stools are rarely present without the use of laxatives

3. There are insufficient criteria for irritable bowel syndrome (IBS)

3. Able and willing to complete a daily e-diary

4. Able and willing to use the trial rescue medication

5. Signed and dated written informed consent prior to enrolment into the study in accordance with GCP and local legislation

At Visit 2, patients must comply with the following additional inclusion criteria to be eligible for entry into the treatment phase:

6. Functional constipation is confirmed by e-diary data at the end of the baseline period:

a. An average of less than 3 CSBMs per week, together with at least one of the following symptoms occurring at least 25% of the time:

• straining

• incomplete evacuation

• lumpy or hard stools (i.e. type 1 or type 2 stools)

7. Compliant with the use of the e-diary throughout the baseline period (compliance is defined as completing 80% of the evening reports)

8. Compliant with the use of rescue medication throughout the baseline period. Compliance is defined as follows:

• rescue medication may be used if there has not been a bowel movement for more than 72 hrs rescue medication may not be used on either day -1 or on the day of randomisation (day 1)

Exclusion Criteria:

1. Eating disorders such as anorexia nervosa and bulimia, as a cause of excessive use of laxatives

2. Patients whose constipation is caused by primary organic disease of the colon or pelvic floor

3. Patients with metabolic disorders, neurological disorders, severe or psychiatric disorders, or any other significant disease or intercurrent illness (e.g. abdominal/gastrointestinal surgery) that, in the Investigators opinion, would interfere with participation in the trial

4. Patients with restricted mobility (e.g. wheelchair bound, or bed-ridden) that, in the Investigators opinion, would interfere with participation in the trial

5. Patients with a known hypersensitivity to bisacodyl or any other ingredient in the study medication

6. Patients with ileus, intestinal obstruction, acute surgical abdominal conditions (such as acute appendicitis and acute inflammatory bowel diseases), or severe dehydration

7. Patients with anal fissures or ulcerative proctitis with mucosal damage

8. Patients with known clinically significant abnormal electrolyte values

9. Patients whose concomitant therapy includes an opioid medication (e.g. morphine, codeine)

10. Constipation which, in the Investigators opinion, is caused by medication (e.g. anticholinergics)

11. Patients who are not willing to discontinue the use of prohibited concomitant therapy

12. Pre-menopausal women who:

1. are nursing (breast-feeding) or who are pregnant OR

2. who are of child-bearing potential and are not practicing an acceptable method of birth control, or do not plan to continue using this method throughout the study. Acceptable methods of birth control include:

• transdermal patch

• intra-uterine devices/systems (IUDs/IUSs)

• oral, implantable or injectable contraceptives

• sexual abstinence

• sterilisation or a vasectomised partner

13. Participation in another trial with an investigational product with 1 month of enrolment into this study

14. Drug or alcohol abuse

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Constipation

Intervention

Drug:
• Bisacodyl 10 mg
2 x 5 mg bisacodyl once daily
• Placebo
Placebo-to-match bisacodyl 10 mg (2 x 5 mg) once daily

Locations

Country	Name	City	State
United Kingdom	122.56.44032 Boehringer Ingelheim Investigational Site	Addlestone
United Kingdom	122.56.44018 Boehringer Ingelheim Investigational Site	Ash Vale, Aldershot
United Kingdom	122.56.44029 Boehringer Ingelheim Investigational Site	Ashford
United Kingdom	122.56.44023 Boehringer Ingelheim Investigational Site	Atherstone
United Kingdom	122.56.44011 Boehringer Ingelheim Investigational Site	Bedworth
United Kingdom	122.56.44009 Boehringer Ingelheim Investigational Site	Bennetthorpe, Doncaster
United Kingdom	122.56.44025 Boehringer Ingelheim Investigational Site	Bexhill on Sea
United Kingdom	122.56.44012 Boehringer Ingelheim Investigational Site	Blackpool
United Kingdom	122.56.44024 Boehringer Ingelheim Investigational Site	Burbage
United Kingdom	122.56.44003 Boehringer Ingelheim Investigational Site	Cardiff
United Kingdom	122.56.44017 Boehringer Ingelheim Investigational Site	Chesterfield
United Kingdom	122.56.44014 Boehringer Ingelheim Investigational Site	Chippenham
United Kingdom	122.56.44006 Boehringer Ingelheim Investigational Site	Chorley
United Kingdom	122.56.44033 Boehringer Ingelheim Investigational Site	Dundee
United Kingdom	122.56.44002 Boehringer Ingelheim Investigational Site	Edgbaston, Birmingham
United Kingdom	122.56.44004 Boehringer Ingelheim Investigational Site	Glasgow
United Kingdom	122.56.44020 Boehringer Ingelheim Investigational Site	Leamington Spa
United Kingdom	122.56.44007 Boehringer Ingelheim Investigational Site	Liverpool
United Kingdom	122.56.44005 Boehringer Ingelheim Investigational Site	Manchester
United Kingdom	122.56.44010 Boehringer Ingelheim Investigational Site	Midsomer Norton
United Kingdom	122.56.44021 Boehringer Ingelheim Investigational Site	Newtonabbey
United Kingdom	122.56.44022 Boehringer Ingelheim Investigational Site	Paignton
United Kingdom	122.56.44001 Boehringer Ingelheim Investigational Site	Slough
United Kingdom	122.56.44026 Boehringer Ingelheim Investigational Site	Sunbury-on-Thames
United Kingdom	122.56.44019 Boehringer Ingelheim Investigational Site	Swindon
United Kingdom	122.56.44015 Boehringer Ingelheim Investigational Site	Warminster
United Kingdom	122.56.44008 Boehringer Ingelheim Investigational Site	Wolverhampton

Sponsors (1)

Lead Sponsor	Collaborator
Boehringer Ingelheim

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Mean Number of Complete Spontaneous Bowel Movements (CSBMs) Per Week Over the 4 Weeks Treatment Period	A Complete Spontaneous Bowel Movement (CSBM) is a complete non-rescue medication-induced stool.; The number of CSBMs in each of the 4 weeks was divided by the number of days where data were available in this week, multiplied by 7 and rounded off to the next integer. The sum of the resulting numbers were divided by the number of weeks with data.	4 Weeks	No
Secondary	Number of CSBMs at Week 1	The number of CSBMs at week 1 was divided by the number of days where data were available in this week, multiplied by 7 and rounded off to the next integer.	Week 1 in treatment period	No
Secondary	Number of CSBMs at Week 2	The number of CSBMs at week 2 was divided by the number of days where data were available in this week, multiplied by 7 and rounded off to the next integer.	Week 2 in treatment period	No
Secondary	Number of CSBMs at Week 3	The number of CSBMs at week 3 was divided by the number of days where data were available in this week, multiplied by 7 and rounded off to the next integer.	Week 3 in treatment period	No
Secondary	Number of CSBMs at Week 4	The number of CSBMs at week 4 was divided by the number of days where data were available in this week, multiplied by 7 and rounded off to the next integer.	Week 4 in treatment period	No
Secondary	Mean Number of SBMs Per Week Over the 4 Weeks Treatment Period	A Spontaneous Bowel Movement (SBM) is a non-rescue medication-induced stool. The number of SBMs in each of the 4 weeks was divided by the number of days where data were available in this week, multiplied by 7 and rounded off to the next integer. The sum of the resulting numbers were divided by the number of weeks with data.	4 Weeks	No
Secondary	Number of SBMs at Week 1	The number of SBMs at week 1 was divided by the number of days where data were available in this week, multiplied by 7 and rounded off to the next integer.	Week 1 in treatment period	No
Secondary	Number of SBMs at Week 2	The number of SBMs at week 2 was divided by the number of days where data were available in this week, multiplied by 7 and rounded off to the next integer.	Week 2 in treatment period	No
Secondary	Number of SBMs at Week 3	The number of SBMs at week 3 was divided by the number of days where data were available in this week, multiplied by 7 and rounded off to the next integer.	Week 3 in treatment period	No
Secondary	Number of SBMs at Week 4	The number of SBMs at week 4 was divided by the number of days where data were available in this week, multiplied by 7 and rounded off to the next integer.	Week 4 in treatment period	No
Secondary	Time to the First SBM Following the First Dose of Study Medication (SM)	The time to the first SBM following the first dose of SM was captured by the eDiary. The time was censored by the time of intake of rescue medication (RM), the time of premature discontinuation or the end of treatment whatever was minimal.	Time of first dose of SM up to 4 weeks	No
Secondary	Number of Participants With an Increase of at Least 1 in the Mean Number of CSBMs Per Week Over the 4 Weeks Treatment Period Compared to Baseline		Baseline and 4 weeks	No
Secondary	Number of Participants With an Increase of at Least 1 CSBM at Week 1 Compared to Baseline		Baseline and week 1 in treatment period	No
Secondary	Number of Participants With an Increase of at Least 1 CSBM at Week 2 Compared to Baseline		Baseline and week 2 in treatment period	No
Secondary	Number of Participants With an Increase of at Least 1 CSBM at Week 3 Compared to Baseline		Baseline and week 3 in treatment period	No
Secondary	Number of Participants With an Increase of at Least 1 CSBM at Week 4 Compared to Baseline		Baseline and week 4 in treatment period	No
Secondary	Number of Participants With a Mean of at Least 1 CSBM a Day Over the 4 Weeks Treatment Period		4 weeks	No
Secondary	Number of Participants With a Mean of at Least 3 CSBMs a Week Over the 4 Weeks Treatment Period		4 weeks	No
Secondary	Number of Premature Withdrawals Over the 4 Weeks Treatment Period		4 weeks	No
Secondary	Number of Premature Withdrawals at Week 1 in the Treatment Period		Week 1 in the treatment period	No
Secondary	Number of Premature Withdrawals at Week 2 in the Treatment Period		Week 2 in the treatment period	No
Secondary	Number of Premature Withdrawals at Week 3 in the Treatment Period		Week 3 in the treatment period	No
Secondary	Number of Premature Withdrawals at Week 4 in the Treatment Period		Week 4 in the treatment period	No
Secondary	Number of Participants Using Rescue Medication Over the 4 Weeks Treatment Period		4 weeks	No
Secondary	Number of Participants Using Rescue Medication at Week 1 in the Treatment Period		Week 1 in the treatment period	No
Secondary	Number of Participants Using Rescue Medication at Week 2 in the Treatment Period		Week 2 in the treatment period	No
Secondary	Number of Participants Using Rescue Medication at Week 3 in the Treatment Period		Week 3 in the treatment period	No
Secondary	Number of Participants Using Rescue Medication at Week 4 in the Treatment Period		Week 4 in the treatment period	No
Secondary	Change From Baseline in the Mean Score for Constipation Symptom 'Straining' at Week 1	The score on a 5-point ordinal verbal rating scale from 0 (absent) to 4 (very severe) specifying patient's symptom assessment associated with each bowel movement was averaged over the day and then averaged over the days in the corresponding week.	Baseline and week 1 in treatment period	No
Secondary	Change From Baseline in the Mean Score for Constipation Symptom 'Straining' at Week 2	The score on a 5-point ordinal verbal rating scale from 0 (absent) to 4 (very severe) specifying patient's symptom assessment associated with each bowel movement was averaged over the day and then averaged over the days in the corresponding week.	Baseline and week 2 in treatment period	No
Secondary	Change From Baseline in the Mean Score for Constipation Symptom 'Straining' at Week 3	The score on a 5-point ordinal verbal rating scale from 0 (absent) to 4 (very severe) specifying patient's symptom assessment associated with each bowel movement was averaged over the day and then averaged over the days in the corresponding week.	Baseline and week 3 in treatment period	No
Secondary	Change From Baseline in the Mean Score for Constipation Symptom 'Straining' at Week 4	The score on a 5-point ordinal verbal rating scale from 0 (absent) to 4 (very severe) specifying patient's symptom assessment associated with each bowel movement was averaged over the day and then averaged over the days in the corresponding week.	Baseline and week 4 in treatment period	No
Secondary	Change From Baseline in the Mean Score for Constipation Symptom 'Stool Quality' at Week 1	The score on the 7-point Bristol Stool Form Scale from Type 1 (hard, lumpy stool) to Type 7 (watery stool) specifying patient's symptom assessment associated with each bowel movement was averaged over the day and then averaged over the days in the corresponding week.	Baseline and week 1 in treatment period	No
Secondary	Change From Baseline in the Mean Score for Constipation Symptom 'Stool Quality' at Week 2	The score on the 7-point Bristol Stool Form Scale from Type 1 (hard, lumpy stool) to Type 7 (watery stool) specifying patient's symptom assessment associated with each bowel movement was averaged over the day and then averaged over the days in the corresponding week.	Baseline and week 2 in treatment period	No
Secondary	Change From Baseline in the Mean Score for Constipation Symptom 'Stool Quality' at Week 3	The score on the 7-point Bristol Stool Form Scale from Type 1 (hard, lumpy stool) to Type 7 (watery stool) specifying patient's symptom assessment associated with each bowel movement was averaged over the day and then averaged over the days in the corresponding week.	Baseline and week 3 in treatment period	No
Secondary	Change From Baseline in the Mean Score for Constipation Symptom 'Stool Quality' at Week 4	The score on the 7-point Bristol Stool Form Scale from Type 1 (hard, lumpy stool) to Type 7 (watery stool) specifying patient's symptom assessment associated with each bowel movement was averaged over the day and then averaged over the days in the corresponding week.	Baseline and week 4 in treatment period	No
Secondary	Change From Baseline in the Mean Score for Constipation Symptom 'Sensation of Incomplete Evacuation' at Week 1	The score on a 2-point ordinal verbal rating scale from 0 (no) to 1 (yes) specifying patient's symptom assessment associated with each bowel movement was averaged over the day and then averaged over the days in the corresponding week.	Baseline and week 1 in treatment period	No
Secondary	Change From Baseline in the Mean Score for Constipation Symptom 'Sensation of Incomplete Evacuation' at Week 2	The score on a 2-point ordinal verbal rating scale from 0 (no) to 1 (yes) specifying patient's symptom assessment associated with each bowel movement was averaged over the day and then averaged over the days in the corresponding week.	Baseline and week 2 in treatment period	No
Secondary	Change From Baseline in the Mean Score for Constipation Symptom 'Sensation of Incomplete Evacuation' at Week 3	The score on a 2-point ordinal verbal rating scale from 0 (no) to 1 (yes) specifying patient's symptom assessment associated with each bowel movement was averaged over the day and then averaged over the days in the corresponding week.	Baseline and week 3 in treatment period	No
Secondary	Change From Baseline in the Mean Score for Constipation Symptom 'Sensation of Incomplete Evacuation' at Week 4	The score on a 2-point ordinal verbal rating scale from 0 (no) to 1 (yes) specifying patient's symptom assessment associated with each bowel movement was averaged over the day and then averaged over the days in the corresponding week.	Baseline and week 4 in treatment period	No
Secondary	Change From Baseline in the Mean Score for Constipation Symptom 'Anorectal Obstructions/Blockade' at Week 1	The score on a 5-point ordinal verbal rating scale from 0 (absent) to 4 (very severe) specifying patient's symptom assessment associated with each bowel movement was averaged over the day and then averaged over the days in the corresponding week.	Baseline and week 1 in treatment period	No
Secondary	Change From Baseline in the Mean Score for Constipation Symptom 'Anorectal Obstructions/Blockade' at Week 2	The score on a 5-point ordinal verbal rating scale from 0 (absent) to 4 (very severe) specifying patient's symptom assessment associated with each bowel movement was averaged over the day and then averaged over the days in the corresponding week.	Baseline and week 2 in treatment period	No
Secondary	Change From Baseline in the Mean Score for Constipation Symptom 'Anorectal Obstructions/Blockade' at Week 3	The score on a 5-point ordinal verbal rating scale from 0 (absent) to 4 (very severe) specifying patient's symptom assessment associated with each bowel movement was averaged over the day and then averaged over the days in the corresponding week.	Baseline and week 3 in treatment period	No
Secondary	Change From Baseline in the Mean Score for Constipation Symptom 'Anorectal Obstructions/Blockade' at Week 4	The score on a 5-point ordinal verbal rating scale from 0 (absent) to 4 (very severe) specifying patient's symptom assessment associated with each bowel movement was averaged over the day and then averaged over the days in the corresponding week.	Baseline and week 4 in treatment period	No
Secondary	Change From Baseline in the Mean Score for Constipation Symptom 'Manual Manoeuvre' at Week 1	The score on a 2-point ordinal verbal rating scale from 0 (no) to 1 (yes) specifying patient's symptom assessment associated with each bowel movement was averaged over the day and then averaged over the days in the corresponding week.	Baseline and week 1 in treatment period	No
Secondary	Change From Baseline in the Mean Score for Constipation Symptom 'Manual Manoeuvre' at Week 2	The score on a 2-point ordinal verbal rating scale from 0 (no) to 1 (yes) specifying patient's symptom assessment associated with each bowel movement was averaged over the day and then averaged over the days in the corresponding week.	Baseline and week 2 in treatment period	No
Secondary	Change From Baseline in the Mean Score for Constipation Symptom 'Manual Manoeuvre' at Week 3	The score on a 2-point ordinal verbal rating scale from 0 (no) to 1 (yes) specifying patient's symptom assessment associated with each bowel movement was averaged over the day and then averaged over the days in the corresponding week.	Baseline and week 3 in treatment period	No
Secondary	Change From Baseline in the Mean Score for Constipation Symptom 'Manual Manoeuvre' at Week 4	The score on a 2-point ordinal verbal rating scale from 0 (no) to 1 (yes) specifying patient's symptom assessment associated with each bowel movement was averaged over the day and then averaged over the days in the corresponding week.	Baseline and week 4 in treatment period	No
Secondary	Number of Participants With Improved, Unchanged or Worsened Overall Satisfaction With Bowel Habits at Week 1 in the Treatment Period in Comparison to Baseline	Improved / unchanged / worsened overall satisfaction is a decreased / unchanged / increased score on a 5-point ordinal VRS: 0 (A very great deal satisfied) to 4 (Not at all satisfied) at the corresponding week in comparison to baseline	Baseline and week 1 in the treatment period	No
Secondary	Number of Participants With Improved, Unchanged or Worsened Overall Satisfaction With Bowel Habits at Week 2 in the Treatment Period in Comparison to Baseline	Improved / unchanged / worsened overall satisfaction is a decreased / unchanged / increased score on a 5-point ordinal VRS: 0 (A very great deal satisfied) to 4 (Not at all satisfied) at the corresponding week in comparison to baseline	Baseline and week 2 in the treatment period	No
Secondary	Number of Participants With Improved, Unchanged or Worsened Overall Satisfaction With Bowel Habits at Week 3 in the Treatment Period in Comparison to Baseline	Improved / unchanged / worsened overall satisfaction is a decreased / unchanged / increased score on a 5-point ordinal VRS: 0 (A very great deal satisfied) to 4 (Not at all satisfied) at the corresponding week in comparison to baseline	Baseline and week 3 in the treatment period	No
Secondary	Number of Participants With Improved, Unchanged or Worsened Overall Satisfaction With Bowel Habits at Week 4 in the Treatment Period in Comparison to Baseline	Improved / unchanged / worsened overall satisfaction is a decreased / unchanged / increased score on a 5-point ordinal VRS: 0 (A very great deal satisfied) to 4 (Not at all satisfied) at the corresponding week in comparison to baseline	Baseline and week 4 in the treatment period	No
Secondary	Number of Participants With Reduced, Unchanged or Increased Bothersomeness With Constipation at Week 1 in the Treatment Period in Comparison to Baseline	Reduced / unchanged / increased bothersomeness of constipation is a decreased / unchanged / increased score on a 5-point ordinal VRS: 0 (Not at all bothersome) to 4 (A very great deal bothersome) at the corresponding week in comparison to baseline	Baseline and week 1 in the treatment period	No
Secondary	Number of Participants With Reduced, Unchanged or Increased Bothersomeness With Constipation at Week 2 in the Treatment Period in Comparison to Baseline	Reduced / unchanged / increased bothersomeness of constipation is a decreased / unchanged / increased score on a 5-point ordinal VRS: 0 (Not at all bothersome) to 4 (A very great deal bothersome) at the corresponding week in comparison to baseline	Baseline and week 2 in the treatment period	No
Secondary	Number of Participants With Reduced, Unchanged or Increased Bothersomeness With Constipation at Week 3 in the Treatment Period in Comparison to Baseline	Reduced / unchanged / increased bothersomeness of constipation is a decreased / unchanged / increased score on a 5-point ordinal VRS: 0 (Not at all bothersome) to 4 (A very great deal bothersome) at the corresponding week in comparison to baseline	Baseline and week 3 in the treatment period	No
Secondary	Number of Participants With Reduced, Unchanged or Increased Bothersomeness With Constipation at Week 4 in the Treatment Period in Comparison to Baseline	Reduced / unchanged / increased bothersomeness of constipation is a decreased / unchanged / increased score on a 5-point ordinal VRS: 0 (Not at all bothersome) to 4 (A very great deal bothersome) at the corresponding week in comparison to baseline	Baseline and week 4 in the treatment period	No
Secondary	Number of Participants With Reduced, Unchanged or Increased Bothersomeness With Abdominal Bloating at Week 1 in the Treatment Period in Comparison to Baseline	Reduced / unchanged / increased bothersomeness of abdominal bloating is a decreased / unchanged / increased score on a 5-point ordinal VRS: 0 (Not at all bothersome) to 4 (A very great deal bothersome) at the corresponding week in comparison to baseline	Baseline and week 1 in the treatment period	No
Secondary	Number of Participants With Reduced, Unchanged or Increased Bothersomeness With Abdominal Bloating at Week 2 in the Treatment Period in Comparison to Baseline	Reduced / unchanged / increased bothersomeness of abdominal bloating is a decreased / unchanged / increased score on a 5-point ordinal VRS: 0 (Not at all bothersome) to 4 (A very great deal bothersome) at the corresponding week in comparison to baseline	Baseline and week 2 in the treatment period	No
Secondary	Number of Participants With Reduced, Unchanged or Increased Bothersomeness With Abdominal Bloating at Week 3 in the Treatment Period in Comparison to Baseline	Reduced / unchanged / increased bothersomeness of abdominal bloating is a decreased / unchanged / increased score on a 5-point ordinal VRS: 0 (Not at all bothersome) to 4 (A very great deal bothersome) at the corresponding week in comparison to baseline	Baseline and week 3 in the treatment period	No
Secondary	Number of Participants With Reduced, Unchanged or Increased Bothersomeness With Abdominal Bloating at Week 4 in the Treatment Period in Comparison to Baseline	Reduced / unchanged / increased bothersomeness of abdominal bloating is a decreased / unchanged / increased score on a 5-point ordinal VRS: 0 (Not at all bothersome) to 4 (A very great deal bothersome) at the corresponding week in comparison to baseline	Baseline and week 4 in the treatment period	No
Secondary	Number of Participants With Reduced, Unchanged or Increased Bothersomeness With Abdominal Discomfort at Week 1 in the Treatment Period in Comparison to Baseline	Reduced / unchanged / increased bothersomeness of abdominal discomfort is a decreased / unchanged / increased score on a 5-point ordinal VRS: 0 (Not at all bothersome) to 4 (A very great deal bothersome) at the corresponding week in comparison to baseline	Baseline and week 1 in the treatment period	No
Secondary	Number of Participants With Reduced, Unchanged or Increased Bothersomeness With Abdominal Discomfort at Week 2 in the Treatment Period in Comparison to Baseline	Reduced / unchanged / increased bothersomeness of abdominal discomfort is a decreased / unchanged / increased score on a 5-point ordinal VRS: 0 (Not at all bothersome) to 4 (A very great deal bothersome) at the corresponding week in comparison to baseline	Baseline and week 2 in the treatment period	No
Secondary	Number of Participants With Reduced, Unchanged or Increased Bothersomeness With Abdominal Discomfort at Week 3 in the Treatment Period in Comparison to Baseline	Reduced / unchanged / increased bothersomeness of abdominal discomfort is a decreased / unchanged / increased score on a 5-point ordinal VRS: 0 (Not at all bothersome) to 4 (A very great deal bothersome) at the corresponding week in comparison to baseline	Baseline and week 3 in the treatment period	No
Secondary	Number of Participants With Reduced, Unchanged or Increased Bothersomeness With Abdominal Discomfort at Week 4 in the Treatment Period in Comparison to Baseline	Reduced / unchanged / increased bothersomeness of abdominal discomfort is a decreased / unchanged / increased score on a 5-point ordinal VRS: 0 (Not at all bothersome) to 4 (A very great deal bothersome) at the corresponding week in comparison to baseline	Baseline and week 4 in the treatment period	No
Secondary	Number of Participants With Respect to the Final Global Assessment of Efficacy by the Investigator	Final global assessment scale range: 1 (good) to 4 (bad), ordinal	4 weeks	No
Secondary	Number of Participants With Respect to the Final Global Assessment of Efficacy by the Patient	Final global assessment scale range: 1 (good) to 4 (bad), ordinal	4 weeks	No
Secondary	Number of Participants With Respect to the Final Global Assessment of Tolerability by the Investigator	Final global assessment scale range: 1 (good) to 4 (bad), ordinal	4 weeks	Yes
Secondary	Number of Participants With Respect to the Final Global Assessment of Tolerability by the Patient	Final global assessment scale range: 1 (good) to 4 (bad), ordinal	4 weeks	Yes
Secondary	Change From Baseline in the SF-36 Dimension 'Physical Functioning'	The dimension is a sum of 10 single items and then transferred to a scale ranging from 0 to 100. Single item scores are inverted, if applicable, to ensure that a higher score indicates a better health.	Baseline and 4 weeks	No
Secondary	Change From Baseline in the SF-36 Dimension 'Role Limitation Due to Physical Problems'	The dimension is a sum of 4 single items and then transferred to a scale ranging from 0 to 100. Single item scores are inverted, if applicable, to ensure that a higher score indicates a better health.	Baseline and 4 weeks	No
Secondary	Change From Baseline in the SF-36 Dimension 'Bodily Pain'	The dimension is a sum of 2 single items and then transferred to a scale ranging from 0 to 100. Single item scores are inverted, if applicable, to ensure that a higher score indicates a better health.	Baseline and 4 weeks	No
Secondary	Change From Baseline in the SF-36 Dimension 'General Health'	The dimension is a sum of 5 single items and then transferred to a scale ranging from 0 to 100. Single item scores are inverted, if applicable, to ensure that a higher score indicates a better health.	Baseline and 4 weeks	No
Secondary	Change From Baseline in the SF-36 Dimension 'Vitality'	The dimension is a sum of 4 single items and then transferred to a scale ranging from 0 to 100. Single item scores are inverted, if applicable, to ensure that a higher score indicates a better health.	Baseline and 4 weeks	No
Secondary	Change From Baseline in the SF-36 Dimension 'Social Functioning'	The dimension is a sum of 2 single items and then transferred to a scale ranging from 0 to 100. Single item scores are inverted, if applicable, to ensure that a higher score indicates a better health.	Baseline and 4 weeks	No
Secondary	Change From Baseline in the SF-36 Dimension 'Role Limitation Due to Emotional Problems'	The dimension is a sum of 3 single items and then transferred to a scale ranging from 0 to 100. Single item scores are inverted, if applicable, to ensure that a higher score indicates a better health.	Baseline and 4 weeks	No
Secondary	Change From Baseline in the SF-36 Dimension 'Mental Health'	The dimension is a sum of 5 single items and then transferred to a scale ranging from 0 to 100. Single item scores are inverted, if applicable, to ensure that a higher score indicates a better health.	Baseline and 4 weeks	No
Secondary	Change From Baseline in the SF-36 Mental Component Scale (MCS)	The MCS is a summary scale of the dimensions vitality, social functioning, role-emotional, and mental health. The component scale is norm-based to a standard population. A higher score indicates a better health.	Baseline and 4 weeks	No
Secondary	Change From Baseline in the SF-36 Physical Component Scale (PCS)	The PCS is a summary scale of the subscales physical functioning, role-physical, bodily pain, and general health. The component scale is norm-based to a standard population. A higher score indicates a better health.	Baseline and 4 weeks	No
Secondary	Change From Baseline in the PAC-QoL Subscale 'Worries and Concerns'	The PAC-QoL is a 28-item (5-point Likert scale ranging from 0 (none of the time or not at all) to 4 (all of the time or extremely). Single item scores are inverted, if applicable, to ensure that a lower score indicates a better QoL	Baseline and 4 weeks	No
Secondary	Change From Baseline in the PAC-QoL Subscale 'Physical Discomfort'	The PAC-QoL is a 28-item (5-point Likert scale ranging from 0 (none of the time or not at all) to 4 (all of the time or extremely). Single item scores are inverted, if applicable, to ensure that a lower score indicates a better QoL	Baseline and 4 weeks	No
Secondary	Change From Baseline in the PAC-QoL Subscale 'Psychosocial Discomfort'	The PAC-QoL is a 28-item (5-point Likert scale ranging from 0 (none of the time or not at all) to 4 (all of the time or extremely). Single item scores are inverted, if applicable, to ensure that a lower score indicates a better QoL	Baseline and 4 weeks	No
Secondary	Change From Baseline in the PAC-QoL Subscale 'Satisfaction'	The PAC-QoL is a 28-item (5-point Likert scale ranging from 0 (none of the time or not at all) to 4 (all of the time or extremely). Single item scores are inverted, if applicable, to ensure that a lower score indicates a better QoL	Baseline and 4 weeks	No
Secondary	Change From Baseline in the PAC-QoL Overall Score	The PAC-QoL is a 28-item (5-point Likert scale ranging from 0 (none of the time or not at all) to 4 (all of the time or extremely). Single item scores are inverted, if applicable, to ensure that a lower score indicates a better QoL	Baseline and 4 weeks	No
Secondary	Change From Baseline for Sodium (Normalized Value)	Normalized value: the reported laboratory value is converted by linear transformation to a preferred unit and then linear-transformed with respect to the standard reference range	Baseline and 4 weeks	No
Secondary	Change From Baseline for Potassium (Normalized Value)	Normalized value: the reported laboratory value is converted by linear transformation to a preferred unit and then linear-transformed with respect to the standard reference range	Baseline and 4 weeks	No
Secondary	Change From Baseline for Chloride (Normalized Value)	Normalized value: the reported laboratory value is converted by linear transformation to a preferred unit and then linear-transformed with respect to the standard reference range	Baseline and 4 weeks	No

External Links

•   Link